EWA
ODT

Evolution Wealth Advisors’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Evolution Wealth Advisors’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-604
Closed -$12K – 675
2020
Q4 		$12K Hold
604
– – ﹤0.01% 334
2020
Q3 		$8K Buy
604
+216
+56% +$6.12K ﹤0.01% 385
2020
Q2 		$16K Hold
388
– – 0.01% 233
2020
Q1 		$11K Buy
388
+228
+143% +$6.65K ﹤0.01% 206
2019
Q4 		$5K Buy
+160
New +$4.96K ﹤0.01% 418

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Evolution Wealth Advisors's ODT Position: Q1 2021 in Review

Evolution Wealth Advisors sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q1 2021, closing a stake of 604 shares — an estimated $12K sold.

Evolution Wealth Advisors first reported a position in ODT in Q4 2019 and held it in 5 quarters. The position peaked at $16K in Q2 2020. 83 funds tracked by Wall St. Rank hold ODT as of Q1 2021.

  • Evolution Wealth Advisors reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Evolution Wealth Advisors sold 604 Odonate Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $12K.
  • Evolution Wealth Advisors first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Evolution Wealth Advisors's Odonate Therapeutics, Inc. Common Stock position peaked at $16K in Q2 2020.
  • 83 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Evolution Wealth Advisors's 13F filing for Q1 2021, filed 20 Apr 2021.